4.7 Meeting Abstract

Results from the first-in-human (FIH) phase I study of the oral RAF inhibitor RAF265 administered daily to patients with advanced cutaneous melanoma

Journal

JOURNAL OF CLINICAL ONCOLOGY
Volume 29, Issue 15, Pages -

Publisher

AMER SOC CLINICAL ONCOLOGY
DOI: 10.1200/jco.2011.29.15_suppl.8508

Keywords

-

Categories

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available